ImmuneBiotech announces the appointment of international microbiome expert Kristin Wannerberger to board of directors

ImmuneBiotech AB

Lund, Sweden, May 10, 2023 – ImmuneBiotech AB, a leading probiotic and microbiome company, is proud to announce the appointment of Dr. Kristin Wannerberger to its board of directors. Dr. Wannerberger is an internationally renowned expert in microbiome research and pharmaceuticals, currently holding a position as Director Alliance Management R&D at Ferring Pharmaceuticals, Switzerland. Her extensive experience and expertise will be instrumental in guiding ImmuneBiotech’s strategic direction and future growth.

”We are thrilled to welcome Dr. Kristin Wannerberger to our Board of Directors”, said Shahram Lavasani, founder and CEO of ImmuneBiotech. ”Her impressive background in the microbiome and pharmaceutical industries, as well as her extensive network across both industry and academia, will have a major impact on ImmuneBiotech’s value and future product development. We look forward to incorporating her expertise in our internationalization and scaling up businesses to further strengthen our global position.”

Dr. Wannerberger’s appointment to the board of directors is part of ImmuneBiotech’s ongoing commitment to expanding its capabilities and driving innovation in the probiotics and microbiome space. It further underscores the dedication to providing the customers with the highest quality products and services.

“I am honored to be joining ImmuneBiotech’s team and to have the opportunity to contribute to the company’s ongoing success,” said Dr. Kristin Wannerberger. “The company has evolved very positively during the last years, and I have great confidence in ImmuneBiotech’s research capabilities. I am excited to work with Shahram and the team to continue developing high-quality probiotics and microbiome solutions that have a positive impact on human health. The upcoming products that ImmuneBiotech is developing are particularly exciting, and I look forward to helping bring them to market.”

Ferring is a leading pharma company in the microbiome space and was the first company to get FDA-approval for a microbial treatment, Rebyota for treatment of Clostridium difficile infection. At Ferring Dr Wannerberger serves as an expert on the microbiome field and she is also directing several external research alliances in the areas of gastrointestinal and reproductive medicine. Dr. Wannerberger is managing a research collaboration with the Karolinska Institute (Stockholm) where the focus is to understand the role of the microbiome in health and disease.

Dr. Wannerberger holds a Ph.D. in Biophysical Technology and a M.Sc. Chemical Engineering Food and Dairy Technology, both from Lund University, Sweden.


About ImmuneBiotech AB – ImmuneBiotech develops, markets, and commercializes therapeutically effective probiotic products that are designed with pharmaceutical precision to effectively manage gastrointestinal and neurological conditions.

Drawing from 20 years of groundbreaking research, ImmuneBiotech has gained a deep understanding of how the microbiome, immune system, and intestinal barrier interact to impact our health and has created a new probiotic category ImmuneBiotics™ where products are developed using pharmaceutical precision focused on achieving a healthy balance between the microbiome, the immune system, and the intestinal barrier. 

GutMagnific® the first product in a new probiotic category ImmuneBiotics™ – GutMagnific is an effective multi-strain probiotic food/nutritional supplement scientifically designed for management of gastrointestinal conditions but has also demonstrated clinical efficacy in neurological conditions.

The unique composition is a result of extensive screening, using pharmaceutical principles for multi-targeted effects to achieve a healthy balance between the microbiome, the immune system, and the intestinal barrier.

GutMagnific is available to primarily Swedish and European consumers on the company’s own web-shop


For more information, please contact:

Shahram Lavasani, CEO

ImmuneBiotech AB

+46 700 90 8946